Limits...
Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity.

Jones DJ, Lamb JH, Verschoyle RD, Howells LM, Butterworth M, Lim CK, Ferry D, Farmer PB, Gescher AJ - Br. J. Cancer (2004)

Bottom Line: Quercetin was less effective, with a 50% decline.Quercetin 3- and 7-O-sulphate had no effect on PGE-2.The results indicate that quercetin may exert its pharmacological effects, at least in part, via its metabolites.

View Article: PubMed Central - PubMed

Affiliation: Cancer Biomarkers and Prevention Group, Department of Biochemistry, Biocentre, University of Leicester, Leicester LE1 7RH, UK. djlj1@le.ac.uk

ABSTRACT
Quercetin (3,5,7,3',4'-pentahydroxyflavone) is a flavone with putative ability to prevent cancer and cardiovascular diseases. Its metabolism was evaluated in rats and human. Rats received quercetin via the intravenous (i.v.) route and metabolites were isolated from the plasma, urine and bile. Analysis was by high-performance liquid chromatography and confirmation of species identity was achieved by mass spectrometry. Quercetin and isorhamnetin, the 3'-O-methyl analogue, were found in both the plasma and urine. In addition, several polar peaks were characterised as sulphated and glucuronidated conjugates of quercetin and isorhamnetin. Extension of the metabolism studies to a cancer patient who had received quercetin as an i.v. bolus showed that (Quercetin removed) isorhamnetin and quercetin 3'-O-sulphate were major plasma metabolites. As a catechol, quercetin can potentially be converted to a quinone and subsequently conjugated with glutathione (GSH). Oxidation of quercetin with mushroom tyrosinase in the presence of GSH furnished GSH conjugates of quercetin, two mono- and one bis-substituted conjugates. However, these species were not found in biomatrices in rats treated with quercetin. As cyclo-oxygenase-2 (COX-2) expression is mechanistically linked to carcinogenesis, we examined whether quercetin and its metabolites can inhibit COX-2 in a human colorectal cancer cell line (HCA-7). Isorhamnetin and its 4'-isomer tamarixetin were potent inhibitors, reflected in a 90% decrease in prostaglandin E-2 (PGE-2) levels, a marker of COX-2 activity. Quercetin was less effective, with a 50% decline. Quercetin 3- and 7-O-sulphate had no effect on PGE-2. The results indicate that quercetin may exert its pharmacological effects, at least in part, via its metabolites.

Show MeSH

Related in: MedlinePlus

High-performance liquid chromatography chromatograms of extracts of plasma from a patient obtained before (bottom trace) and 5 min after administration (top trace) of quercetin (280 mg m−2 i.v.). Peaks were identified on the basis of cochromatography and selected ion monitoring MS, which afforded m/z 301 for quercetin, m/z 315 for isorhamnetin and m/z 381 for quercetin 3-O-sulphate. AU=absorbance units. For details of sample preparation and chromatographic and mass spectrometric analysis see Materials and Methods.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747694&req=5

fig4: High-performance liquid chromatography chromatograms of extracts of plasma from a patient obtained before (bottom trace) and 5 min after administration (top trace) of quercetin (280 mg m−2 i.v.). Peaks were identified on the basis of cochromatography and selected ion monitoring MS, which afforded m/z 301 for quercetin, m/z 315 for isorhamnetin and m/z 381 for quercetin 3-O-sulphate. AU=absorbance units. For details of sample preparation and chromatographic and mass spectrometric analysis see Materials and Methods.

Mentions: A patient with confirmed cancer received quercetin via the i.v. route. Extracts of plasma obtained just prior to, and 5 min after, drug administration were analysed by HPLC (Figure 4Figure 4


Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity.

Jones DJ, Lamb JH, Verschoyle RD, Howells LM, Butterworth M, Lim CK, Ferry D, Farmer PB, Gescher AJ - Br. J. Cancer (2004)

High-performance liquid chromatography chromatograms of extracts of plasma from a patient obtained before (bottom trace) and 5 min after administration (top trace) of quercetin (280 mg m−2 i.v.). Peaks were identified on the basis of cochromatography and selected ion monitoring MS, which afforded m/z 301 for quercetin, m/z 315 for isorhamnetin and m/z 381 for quercetin 3-O-sulphate. AU=absorbance units. For details of sample preparation and chromatographic and mass spectrometric analysis see Materials and Methods.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747694&req=5

fig4: High-performance liquid chromatography chromatograms of extracts of plasma from a patient obtained before (bottom trace) and 5 min after administration (top trace) of quercetin (280 mg m−2 i.v.). Peaks were identified on the basis of cochromatography and selected ion monitoring MS, which afforded m/z 301 for quercetin, m/z 315 for isorhamnetin and m/z 381 for quercetin 3-O-sulphate. AU=absorbance units. For details of sample preparation and chromatographic and mass spectrometric analysis see Materials and Methods.
Mentions: A patient with confirmed cancer received quercetin via the i.v. route. Extracts of plasma obtained just prior to, and 5 min after, drug administration were analysed by HPLC (Figure 4Figure 4

Bottom Line: Quercetin was less effective, with a 50% decline.Quercetin 3- and 7-O-sulphate had no effect on PGE-2.The results indicate that quercetin may exert its pharmacological effects, at least in part, via its metabolites.

View Article: PubMed Central - PubMed

Affiliation: Cancer Biomarkers and Prevention Group, Department of Biochemistry, Biocentre, University of Leicester, Leicester LE1 7RH, UK. djlj1@le.ac.uk

ABSTRACT
Quercetin (3,5,7,3',4'-pentahydroxyflavone) is a flavone with putative ability to prevent cancer and cardiovascular diseases. Its metabolism was evaluated in rats and human. Rats received quercetin via the intravenous (i.v.) route and metabolites were isolated from the plasma, urine and bile. Analysis was by high-performance liquid chromatography and confirmation of species identity was achieved by mass spectrometry. Quercetin and isorhamnetin, the 3'-O-methyl analogue, were found in both the plasma and urine. In addition, several polar peaks were characterised as sulphated and glucuronidated conjugates of quercetin and isorhamnetin. Extension of the metabolism studies to a cancer patient who had received quercetin as an i.v. bolus showed that (Quercetin removed) isorhamnetin and quercetin 3'-O-sulphate were major plasma metabolites. As a catechol, quercetin can potentially be converted to a quinone and subsequently conjugated with glutathione (GSH). Oxidation of quercetin with mushroom tyrosinase in the presence of GSH furnished GSH conjugates of quercetin, two mono- and one bis-substituted conjugates. However, these species were not found in biomatrices in rats treated with quercetin. As cyclo-oxygenase-2 (COX-2) expression is mechanistically linked to carcinogenesis, we examined whether quercetin and its metabolites can inhibit COX-2 in a human colorectal cancer cell line (HCA-7). Isorhamnetin and its 4'-isomer tamarixetin were potent inhibitors, reflected in a 90% decrease in prostaglandin E-2 (PGE-2) levels, a marker of COX-2 activity. Quercetin was less effective, with a 50% decline. Quercetin 3- and 7-O-sulphate had no effect on PGE-2. The results indicate that quercetin may exert its pharmacological effects, at least in part, via its metabolites.

Show MeSH
Related in: MedlinePlus